Skip to main content

Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients

Infection volume 46, pages 431–434 (2018)Cite this article

Abstract

Multidrug-resistant (MDR) Pseudomonas aeruginosa infection causes significant mortality among patients with hematologic malignancies and hematopoietic-cell transplant recipients. Ceftolozane-tazobactam (C-T) is a novel therapeutic option for MDR-P. aeruginosa infections but clinical experience in these patients is limited. We report favorable clinical outcomes and lack of limiting toxicities using C-T monotherapy to treat invasive MDR-P. aeruginosa infections in these patient populations.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Satlin MJ, Walsh TJ. Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: three major threats to hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2017. https://doi.org/10.1111/tid.12762.

    PubMed  Article  Google Scholar 

  2. Cattaneo C, Antoniazzi F, Casari S, Ravizzola G, Gelmi M, Pagani C, et al. P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol. 2012;91:1299–304. https://doi.org/10.1007/s00277-012-1424-3.

    Article  PubMed  Google Scholar 

  3. Trecarichi EM, Tumbarello M, Caira M, Candoni A, Cattaneo C, Pastore D, et al. Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica. 2011;96:e1–3. https://doi.org/10.3324/haematol.2010.036640 author reply e4.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Trecarichi EM, Tumbarello M. Antimicrobial-resistant gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact. Curr Opin Infect Dis. 2014;27:200–10. https://doi.org/10.1097/QCO.0000000000000038.

    Article  PubMed  CAS  Google Scholar 

  5. Pfaller MA, Bassetti M, Duncan LR, Castanheira M. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012–15). J Antimicrob Chemother. 2017;72:1386–95. https://doi.org/10.1093/jac/dkx009.

    Article  PubMed  CAS  Google Scholar 

  6. Sader HS, Farrell DJ, Castanheira M, Flamm RK, Jones RN. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011–12). J Antimicrob Chemother. 2014;69:2713–22. https://doi.org/10.1093/jac/dku184.

    Article  PubMed  CAS  Google Scholar 

  7. Shortridge D, Castanheira M, Pfaller MA, Flamm RK. Ceftolozane-tazobactam activity against Pseudomonas aeruginosa clinical isolates from US hospitals: report from the PACTS antimicrobial surveillance program, 2012 to 2015. Antimicrob Agents Chemother. 2017. https://doi.org/10.1128/aac.00465-17.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Aitken SL, Kontoyiannis DP, DePombo AM, Bhatti MM, Tverdek FP, Gettys SC, et al. Use of ceftolozane/tazobactam in the treatment of multidrug-resistant Pseudomonas aeruginosa bloodstream infection in a pediatric leukemia patient. Pediatr Infect Dis J. 2016;35:1040–2. https://doi.org/10.1097/INF.0000000000001228.

    Article  PubMed  Google Scholar 

  9. Caston JJ, De la Torre A, Ruiz-Camps I, Sorli ML, Torres V, Torre-Cisneros J. Salvage therapy with ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections. Antimicrob Agents Chemother. 2017. https://doi.org/10.1128/aac.02136-16.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Dinh A, Wyplosz B, Kerneis S, Lebeaux D, Bouchand F, Duran C, et al. Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents. 2017;49:782–3. https://doi.org/10.1016/j.ijantimicag.2017.04.001.

    Article  PubMed  CAS  Google Scholar 

  11. Haidar GP, Philips NJ, Shields RK, Snyder D, Cheng S, Potoski BA, et al. Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis. 2017;65:110–20.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Munita JM, Aitken SL, Miller WR, Perez F, Rosa R, Shimose LA, et al. Multicenter evaluation of ceftolozane/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2017. https://doi.org/10.1093/cid/cix014.

    PubMed Central  Article  PubMed  Google Scholar 

  13. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268–81. https://doi.org/10.1111/j.1469-0691.2011.03570.x.

    Article  PubMed  CAS  Google Scholar 

  14. Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, et al. Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica. 2010;95:1612–5. https://doi.org/10.3324/haematol.2009.020867.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  15. Mikulska M, Del Bono V, Bruzzi P, Raiola AM, Gualandi F, Van Lint MT, et al. Mortality after bloodstream infections in allogeneic haematopoietic stem cell transplant (HSCT) recipients. Infection. 2012;40:271–8. https://doi.org/10.1007/s15010-011-0229-y.

    Article  PubMed  CAS  Google Scholar 

  16. Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, Occhini D, et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transp. 2009;15:47–53. https://doi.org/10.1016/j.bbmt.2008.10.024.

    Article  CAS  Google Scholar 

  17. Hakki M, Limaye AP, Kim HW, Kirby KA, Corey L, Boeckh M. Invasive Pseudomonas aeruginosa infections: high rate of recurrence and mortality after hematopoietic cell transplantation. Bone Marrow Transp. 2007;39:687–93. https://doi.org/10.1038/sj.bmt.1705653.

    Article  CAS  Google Scholar 

  18. MacVane SH, Pandey R, Steed LL, Kreiswirth BN, Chen L. Emergence of ceftolozane-tazobactam resistant Pseudomonas aeruginosa during treatment is mediated by a single AmpC structural mutation. Antimicrob Agents Chemother. 2017. https://doi.org/10.1128/AAC.01183-17.

    PubMed  PubMed Central  Article  Google Scholar 

  19. Merck & Co. I. Zerbaxa package insert. 2015.

  20. Xiao AJ, Miller BW, Huntington JA, Nicolau DP. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. J Clin Pharmacol. 2016;56:56–66. https://doi.org/10.1002/jcph.566.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Affiliations

  1. Division of Infectious Diseases, Department of Internal Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Mail Code L457, Portland, OR, 97239, USA

    Morgan Hakki

  2. Department of Pharmacy, Oregon Health and Science University, Portland, OR, USA

    James S. Lewis II.

Authors
  1. Morgan Hakki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James S. Lewis II.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Morgan Hakki.

Ethics declarations

Conflict of interest

JSL has served as a consultant for Merck. MH has no relevant conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Hakki, M., Lewis, J.S. Ceftolozane-tazobactam therapy for multidrug-resistant Pseudomonas aeruginosa infections in patients with hematologic malignancies and hematopoietic-cell transplant recipients. Infection 46, 431–434 (2018). https://doi.org/10.1007/s15010-018-1125-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15010-018-1125-5

Keywords

  • Ceftolozane-tazobactam
  • Pseudomonas aeruginosa
  • Hematologic malignancy
  • Hematopoietic-cell transplant